- Home
- WBS vs AXSM Comparison
WBS vs AXSM Comparison
Compare WBS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WBS | AXSM |
|---|---|---|
| Founded | 1935 | 2012 |
| Country | United States | United States |
| Employees | 4601 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 12.0B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | WBS | AXSM |
|---|---|---|
| Price | $75.92 | $229.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 17 |
| Target Price | $73.64 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 3.0M | 878.2K |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.32 | $57.24 |
| Revenue Next Year | $5.89 | $55.88 |
| P/E Ratio | $12.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $52.69 | $96.09 |
| 52 Week High | $77.69 | $260.19 |
Technical Indicators
Market Signals| Indicator | WBS | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 42.60 |
| Support Level | $75.18 | $217.15 |
| Resistance Level | $76.13 | $236.26 |
| Average True Range (ATR) | 0.64 | 9.67 |
| MACD | -0.18 | -2.07 |
| Stochastic Oscillator | 26.14 | 18.57 |
Price Performance
Historical ComparisonAbout WBS Webster Financial Corporation
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.